ATE307119T1 - Bicyclische protein-farnesyl-transferase inhibitoren - Google Patents
Bicyclische protein-farnesyl-transferase inhibitorenInfo
- Publication number
- ATE307119T1 ATE307119T1 AT98906491T AT98906491T ATE307119T1 AT E307119 T1 ATE307119 T1 AT E307119T1 AT 98906491 T AT98906491 T AT 98906491T AT 98906491 T AT98906491 T AT 98906491T AT E307119 T1 ATE307119 T1 AT E307119T1
- Authority
- AT
- Austria
- Prior art keywords
- pct
- transferase inhibitors
- farnesyl transferase
- present
- protein farnesyl
- Prior art date
Links
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3750497P | 1997-02-11 | 1997-02-11 | |
| PCT/US1998/003025 WO1998034921A1 (en) | 1997-02-11 | 1998-02-11 | Bicyclic inhibitors of protein farnesyl transferase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE307119T1 true ATE307119T1 (de) | 2005-11-15 |
Family
ID=21894697
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT98906491T ATE307119T1 (de) | 1997-02-11 | 1998-02-11 | Bicyclische protein-farnesyl-transferase inhibitoren |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US6133303A (de) |
| EP (1) | EP0966446B1 (de) |
| JP (1) | JP2001518076A (de) |
| KR (1) | KR20000070924A (de) |
| AT (1) | ATE307119T1 (de) |
| AU (1) | AU725696B2 (de) |
| BR (1) | BR9807674A (de) |
| CA (1) | CA2273895A1 (de) |
| DE (1) | DE69831937T2 (de) |
| ES (1) | ES2252827T3 (de) |
| NZ (1) | NZ336134A (de) |
| WO (1) | WO1998034921A1 (de) |
| ZA (1) | ZA981080B (de) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2478500A (en) | 1998-12-08 | 2000-06-26 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| WO2000034437A2 (en) | 1998-12-08 | 2000-06-15 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| US6943183B2 (en) | 2000-04-17 | 2005-09-13 | Pfizer Inc | 5-substituted tetralones as inhibitors of ras farnesyl transferase |
| US20030232790A1 (en) * | 2000-04-17 | 2003-12-18 | Leonard Daniele Marie | Dihydro-2h-napthalene-1-one inhibitors of ras farnesyl transferase |
| US7425618B2 (en) | 2002-06-14 | 2008-09-16 | Medimmune, Inc. | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
| US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
| US20040265315A1 (en) * | 2002-09-05 | 2004-12-30 | Christine Dingivan | Methods of preventing or treating T cell malignancies by administering CD2 antagonists |
| US7563810B2 (en) | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
| US8034831B2 (en) | 2002-11-06 | 2011-10-11 | Celgene Corporation | Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies |
| EP1613273B1 (de) | 2003-04-11 | 2012-06-13 | MedImmune, LLC | Rekombinante il-9-antikörper und ihre verwendung |
| EP1660186B1 (de) | 2003-08-18 | 2013-12-25 | MedImmune, LLC | Humanisierung von antikörpern |
| US7550482B2 (en) * | 2004-02-27 | 2009-06-23 | Merz Pharma Gmbh & Co. Kgaa | Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors |
| US20060004001A1 (en) * | 2004-02-27 | 2006-01-05 | Merz Pharma Gmbh & Co., Kgaa | Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors |
| EP2422811A2 (de) | 2004-10-27 | 2012-02-29 | MedImmune, LLC | Modulation von Antikörperspezifität mittels Anpassung der Affinität zu verwandten Antigenen |
| EP1869192B1 (de) | 2005-03-18 | 2016-01-20 | MedImmune, LLC | Rahmenmischung von antikörpern |
| AU2006261920A1 (en) | 2005-06-23 | 2007-01-04 | Medimmune, Llc | Antibody formulations having optimized aggregation and fragmentation profiles |
| US20070117835A1 (en) * | 2005-10-04 | 2007-05-24 | David Hung | Methods and compositions for treating Huntington's disease |
| EA021255B1 (ru) | 2006-08-28 | 2015-05-29 | Киова Хакко Кирин Ко., Лимитед | Антагонистические моноклональные антитела человека, специфичные в отношении light человека |
| AU2008232903B9 (en) | 2007-03-30 | 2013-09-05 | Medimmune Llc | Antibodies with decreased deamidation profiles |
| MX2010004374A (es) | 2007-10-31 | 2010-04-30 | Medimmune Llc | Armazones proteinicos. |
| AU2009268406A1 (en) * | 2008-07-10 | 2010-01-14 | Southern Research Institute | 5-Quinolinone and Imidazopyridine compounds and use thereof |
| US8725967B2 (en) * | 2008-08-08 | 2014-05-13 | Amazon Technologies, Inc. | Providing executing programs with access to stored block data of others |
| AR085091A1 (es) | 2011-01-26 | 2013-09-11 | Kolltan Pharmaceuticals Inc | Anticuerpos anti-kit y sus usos |
| RU2681730C2 (ru) | 2012-07-25 | 2019-03-12 | Селлдекс Терапьютикс Инк. | Антитела против kit и их применения |
| CA2887129A1 (en) | 2012-10-09 | 2014-04-17 | Igenica, Inc. | Anti-c16orf54 antibodies and methods of use thereof |
| JP6824735B2 (ja) | 2013-06-06 | 2021-02-03 | ピエール、ファーブル、メディカマン | 抗Ｃ１０ｏｒｆ５４抗体およびその使用方法 |
| US9475874B2 (en) | 2013-08-26 | 2016-10-25 | MabVax Therapeutics, Inc. | Nucleic acids encoding human antibodies to sialyl-lewisa |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| CA2950602C (en) | 2014-06-04 | 2021-07-20 | MabVax Therapeutics, Inc. | Human monoclonal antibodies to ganglioside gd2 |
| CA2970352A1 (en) | 2014-12-11 | 2016-06-16 | Pierre Fabre Medicament | Anti-c10orf54 antibodies and uses thereof |
| HRP20230046T1 (hr) | 2015-03-03 | 2023-03-03 | Kymab Limited | Protutijela, upotreba i postupci |
| CN114470194A (zh) | 2015-12-02 | 2022-05-13 | 斯特库伯株式会社 | 与btn1a1免疫特异性结合的抗体和分子及其治疗用途 |
| US11253590B2 (en) | 2015-12-02 | 2022-02-22 | Stsciences, Inc. | Antibodies specific to glycosylated BTLA (B- and T- lymphocyte attenuator) |
| CN105801421A (zh) * | 2016-03-31 | 2016-07-27 | 常州大学 | 一种2-醛基-3-羟基-4,6-二氯苯甲酸的合成方法 |
| US11779604B2 (en) | 2016-11-03 | 2023-10-10 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses and methods |
| EP3630834A1 (de) | 2017-05-31 | 2020-04-08 | STCube & Co., Inc. | Verfahren zur behandlung von krebs mit antikörpern und molekülen, die immunspezifisch an btn1a1 binden |
| WO2018222689A1 (en) | 2017-05-31 | 2018-12-06 | Stcube & Co., Inc. | Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof |
| CN121609797A (zh) | 2017-06-06 | 2026-03-06 | 斯特库伯株式会社 | 使用结合btn1a1或btn1a1-配体的抗体和分子治疗癌症的方法 |
| EP3694889A1 (de) | 2017-10-13 | 2020-08-19 | Boehringer Ingelheim International GmbH | Humane antikörper gegen thomsen-nouvelle (tn)-antigen |
| MA53160A (fr) | 2018-07-20 | 2021-05-26 | Pf Medicament | Récepteur pour vista |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH535225A (de) * | 1969-03-29 | 1973-03-31 | Schering Ag | Verfahren zur Herstellung von heterocyclischen Nitroverbindungen |
| DE1937630A1 (de) * | 1969-07-19 | 1971-02-04 | Schering Ag | 2-(5-Nitro-2-furfuryliden)-l-tetralone |
| JPS6013788A (ja) * | 1983-07-05 | 1985-01-24 | Yamanouchi Pharmaceut Co Ltd | 新規なクマリン誘導体 |
| BR8305086A (pt) | 1983-09-19 | 1984-03-20 | Antonio Signori | Dispositivo de amortecimento aplicavel a calcados em geral |
| ES539074A0 (es) * | 1984-12-10 | 1985-11-16 | Ferrer Int | Procedimiento de obtencion de nuevos derivados imidazoliletoxiindanicos. |
| US5059609A (en) * | 1987-10-19 | 1991-10-22 | Pfizer Inc. | Substituted tetralins, chromans and related compounds in the treatment of asthma, arthritis and related diseases |
| MX13485A (es) * | 1987-10-19 | 1993-05-01 | Pfizer | Procedimiento para obtener tetralinas, cromados y compuestos relacionados, sustituidos |
| GB2244431A (en) * | 1990-05-31 | 1991-12-04 | Farmos Oy | Treatment of age related memory impairment and other cognitive disorders |
| US5149703A (en) * | 1991-09-06 | 1992-09-22 | Merck Frosst Canada, Inc. | Quinoline-substituted chromans and related compounds as leukotriene antagonists |
| USRE37303E1 (en) * | 1992-01-10 | 2001-07-31 | Institut National Del La Sante Et De La Recherche Medicale | Imidazole compounds and their therapeutic applications |
| CZ100095A3 (en) * | 1992-10-21 | 1995-11-15 | Pfizer | Sulfonamide derivatives of hydroxy substituted alicyclic or heterocyclic compounds with condensed benzene nucleus and pharmaceutical preparations based thereon |
| WO1995033748A1 (en) * | 1994-06-09 | 1995-12-14 | Smithkline Beecham Corporation | Endothelin receptor antagonists |
| EP0695753A1 (de) * | 1994-08-05 | 1996-02-07 | Zeneca Limited | Carbapenem-Derivate mit einem bicyclischen Substituenten, Verfahren zu ihrer Herstellung und ihre Verwendung |
| GB9425211D0 (en) * | 1994-12-14 | 1995-02-15 | Ucb Sa | Substituted 1H-imidazoles |
| GB9520150D0 (en) * | 1995-10-03 | 1995-12-06 | Orion Yhtymae Oy | New imidazole derivatives |
| DK0873123T3 (da) * | 1995-11-06 | 2003-08-04 | Univ Pittsburgh | Inhibitorer af protein-isoprenyltransferaser |
| JP2000504017A (ja) * | 1996-01-30 | 2000-04-04 | メルク エンド カンパニー インコーポレーテッド | ファルネシル―タンパク質転移酵素の阻害剤 |
| AU707416B2 (en) * | 1996-04-03 | 1999-07-08 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US5977134A (en) * | 1996-12-05 | 1999-11-02 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US6127390A (en) * | 1997-10-02 | 2000-10-03 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| AU9452998A (en) * | 1997-10-22 | 1999-05-10 | Zeneca Limited | Imidazole derivatives and their use as farnesyl protein transferase inhibit ors |
| FR2787451B1 (fr) * | 1998-12-18 | 2001-01-26 | Adir | Nouveaux composes imidazoliniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US6143766A (en) * | 1999-04-16 | 2000-11-07 | Warner-Lambert Company | Benzopyranone and quinolone inhibitors of ras farnesyl transferase |
| US6403581B1 (en) * | 2000-01-19 | 2002-06-11 | American Cyanamid Company | Method of inhibition of farnesyl-protein transferase using substituted benz (cd) indol-2-imine and-amine derivatives |
-
1998
- 1998-02-10 ZA ZA981080A patent/ZA981080B/xx unknown
- 1998-02-11 AU AU61704/98A patent/AU725696B2/en not_active Ceased
- 1998-02-11 DE DE69831937T patent/DE69831937T2/de not_active Expired - Fee Related
- 1998-02-11 CA CA002273895A patent/CA2273895A1/en not_active Abandoned
- 1998-02-11 BR BR9807674-4A patent/BR9807674A/pt not_active IP Right Cessation
- 1998-02-11 WO PCT/US1998/003025 patent/WO1998034921A1/en not_active Ceased
- 1998-02-11 EP EP98906491A patent/EP0966446B1/de not_active Expired - Lifetime
- 1998-02-11 NZ NZ336134A patent/NZ336134A/en unknown
- 1998-02-11 KR KR1019997007189A patent/KR20000070924A/ko not_active Ceased
- 1998-02-11 US US09/355,662 patent/US6133303A/en not_active Expired - Fee Related
- 1998-02-11 JP JP53510598A patent/JP2001518076A/ja not_active Abandoned
- 1998-02-11 AT AT98906491T patent/ATE307119T1/de not_active IP Right Cessation
- 1998-02-11 ES ES98906491T patent/ES2252827T3/es not_active Expired - Lifetime
-
2000
- 2000-04-28 US US09/560,606 patent/US6265422B1/en not_active Expired - Fee Related
-
2001
- 2001-07-23 US US09/910,967 patent/US6528535B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20020006936A1 (en) | 2002-01-17 |
| DE69831937D1 (de) | 2006-03-02 |
| BR9807674A (pt) | 2000-02-15 |
| JP2001518076A (ja) | 2001-10-09 |
| US6133303A (en) | 2000-10-17 |
| AU6170498A (en) | 1998-08-26 |
| US6528535B2 (en) | 2003-03-04 |
| AU725696B2 (en) | 2000-10-19 |
| NZ336134A (en) | 2001-08-31 |
| CA2273895A1 (en) | 1998-08-13 |
| EP0966446B1 (de) | 2005-10-19 |
| DE69831937T2 (de) | 2006-07-27 |
| WO1998034921A1 (en) | 1998-08-13 |
| ES2252827T3 (es) | 2006-05-16 |
| EP0966446A1 (de) | 1999-12-29 |
| ZA981080B (en) | 1998-08-12 |
| US6265422B1 (en) | 2001-07-24 |
| KR20000070924A (ko) | 2000-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE307119T1 (de) | Bicyclische protein-farnesyl-transferase inhibitoren | |
| DE69516866D1 (de) | Stereochemische wortmanninderivate | |
| ATE259826T1 (de) | Glycinamidederivate mit funktionalisierter alkyl- und alkenylseitenkette als inhibitoren der farnesyltransferase | |
| NO996578L (no) | Urokinase-inhibitorer | |
| UA29446C2 (uk) | Засіб для інгібування тромбіну | |
| NZ294933A (en) | Thienopyridine or thienopyrimidine derivatives, pharmaceutical compositions and use as anti-inflammatory agents | |
| KR950702180A (ko) | 류코트리엔 생합성 억제제로서의 치환된 아릴알키닐-및 헤테로아릴알키닐-N-하이드록시우레아(substituted arylalkynyl-and heteroarylalkyny-N-hydroxyurea inhibi tors of leukotriene biosynthesis)본 내용은 요부공개 건이므로 전문 내용을 수록하지 않았음 | |
| DE69719358D1 (de) | Substituierte dihydrobenzofurane als pde-hemmstoffe | |
| MX9602861A (es) | Mezcla estabilizante sinergistica. | |
| ATE303362T1 (de) | Chalcon-derivate mit antiproliferativer aktivität | |
| ATE219481T1 (de) | 1,7,7-trimethyl-bicyclo(2.2.1)heptane derivative | |
| PL331347A1 (en) | Derivatives of n-benzene sulphonyl-l-proline | |
| CY2225B1 (en) | Organic compounds | |
| NO952427L (no) | Metode for behandling av kronisk prostatitt med 17 substituerte karbamoyl-4-aza-5 | |
| BR9906803A (pt) | Processo para tratamento de copd | |
| SE9704770D0 (sv) | New use | |
| SE9700706D0 (sv) | Process for the preparation of benzothiazoline compounds | |
| AU2576901A (en) | Agents and methods for the treatment of proliferative diseases | |
| DE69528984D1 (de) | Hemmung der leukotrienbiosynthese mittels harnstoffderivaten | |
| ATE293605T1 (de) | Fluorierte 3,4-dihydrochinolin-derivative als nos-inhibitoren |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |